Xylo Technologies Ltd

NasdaqCM:XYLO Stock Report

Market Cap: US$2.2m

Xylo Technologies Past Earnings Performance

Past criteria checks 0/6

Xylo Technologies's earnings have been declining at an average annual rate of -14.5%, while the Medical Equipment industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 62.3% per year.

Key information

-14.5%

Earnings growth rate

43.9%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate62.3%
Return on equity-151.3%
Net Margin-27.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its Profitability

Sep 28
We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its Profitability

Recent updates

Medigus says ScoutCam appoints Yehu Ofer as CEO

Oct 19

Medigus reports 1H results

Sep 23

What Does Medigus Ltd.'s (NASDAQ:MDGS) Share Price Indicate?

Sep 22
What Does Medigus Ltd.'s (NASDAQ:MDGS) Share Price Indicate?

Medigus board files a motion to approve an up to $1.6M dividend distribution

Sep 08

Is Now An Opportune Moment To Examine Medigus Ltd. (NASDAQ:MDGS)?

May 10
Is Now An Opportune Moment To Examine Medigus Ltd. (NASDAQ:MDGS)?

We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its Profitability

Sep 28
We Believe Medigus' (NASDAQ:MDGS) Earnings Are A Poor Guide For Its Profitability

Medigus jumps 4% as subsidiary Charging Robotics assigns first distributor for its wireless EV robotic charging pad

Jun 17

Medigus launches ADS offering

Jan 11

Medigus expands EV operations with acquisition of autonomous technology, shares up 31%

Jan 08

New finance cheif at Medigus

Dec 01

Medigus shares +42% on plans to enter micro-mobility EV market

Nov 19

Medigus under pressure after increasing stake to ~33% in Polyrizon

Nov 09

Revenue & Expenses Breakdown

How Xylo Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:XYLO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2458-16145
31 Mar 2475-16155
31 Dec 2392-16176
30 Sep 23101-15196
30 Jun 23110-14206
31 Mar 23101-12196
31 Dec 2292-10185
30 Sep 2267-8164
30 Jun 2243-7143
31 Mar 22260132
31 Dec 21107121
30 Sep 2167101
30 Jun 213881
31 Mar 212271
31 Dec 201-461
30 Sep 200-1051
30 Jun 200-1550
31 Mar 200-1541
31 Dec 190-1431
30 Sep 190-941
30 Jun 190-651
31 Mar 190-652
31 Dec 180-752
30 Sep 180-642
30 Jun 180-432
31 Mar 180-232
31 Dec 170-342
30 Sep 170-442
30 Jun 170-552
31 Mar 170-853
31 Dec 161-964
30 Sep 161-1074
30 Jun 161-1075
31 Mar 161-1065
31 Dec 151-1064
30 Sep 151-854
30 Jun 150-754
31 Mar 150-644
31 Dec 141-654
30 Sep 141-544
30 Jun 141-544
31 Mar 141-233
31 Dec 131-132

Quality Earnings: XYLO is currently unprofitable.

Growing Profit Margin: XYLO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: XYLO is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare XYLO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XYLO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).


Return on Equity

High ROE: XYLO has a negative Return on Equity (-151.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies